BAP-1 mutations, which have been associated with poor prognosis in ccRCC (34, 35), were observed in 10% of tumors in the overall cohort, consistent with prior studies (16, 36–38), and no differential expression was seen between the primary renal tumors versus sites of metastasis. The gene discussed is BAP1; the disease is kidney neoplasm.